<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814639/" ref="ordinalpos=4930&amp;ncbi_uid=6032993&amp;link_uid=PMC3814639" image-link="/pmc/articles/PMC3814639/figure/F2/" class="imagepopup">Figure 2. From: The emerging role of the Nrf2-Keap1 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in cancer. </a></div><br /><div class="p4l_captionBody">Schematic model of the Nrf2–Keap1 signaling pathway. Under basal conditions, Keap1 binds to the ETGE and DLG motifs on Nrf2 and brings Nrf2 into Keap1–Cul3–E3 ubiquitin ligase complex, leading to ubiquitination and subsequent degradation of Nrf2. Oxidative stress or electrophiles can cause a conformational change in the Keap1–Cul3–E3 ubiquitin ligase by acting on specific cysteine residues in Keap1. These changes disrupt Nrf2–Keap1 binding at the DLG domain. Nrf2 is stabilized, and free Nrf2 translocates to the nucleus, where it dimerizes with members of the small Maf family and binds to AREs (5′-RTGABNNNGCR-3′) within regulatory regions of a wide variety of cell defense genes, including NQO1, GCLM, HO-1, and MRP1. (E) ETGE; (D) DLG.</div></div>